{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:13:53Z","timestamp":1757625233026,"version":"3.44.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s13304-025-02238-6","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:02:00Z","timestamp":1747285320000},"page":"1413-1420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of preoperative use of biologics on 30-day surgical morbidity and mortality in patients with Crohn\u2019s disease undergoing ileocolectomy: National Surgical Quality Improvement Program database analysis"],"prefix":"10.1007","volume":"77","author":[{"given":"Fady","family":"Daniel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zakaria","family":"El Kouzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamil","family":"Mrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad Ali","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala I.","family":"Sharara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walaa","family":"El Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Khalife","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Tamim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"4","key":"2238_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/ajg.2015.50","volume":"110","author":"FT Moller","year":"2015","unstructured":"Moller FT et al (2015) Familial risk of inflammatory bowel disease: a population-based cohort study 1977\u20132011. Am J Gastroenterol 110(4):564\u2013571","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2238_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA et al (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1):46\u201354","journal-title":"Gastroenterology"},{"issue":"2","key":"2238_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","volume":"152","author":"GG Kaplan","year":"2017","unstructured":"Kaplan GG, Ng SC (2017) Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 152(2):313-321.e2","journal-title":"Gastroenterology"},{"issue":"1","key":"2238_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J et al (2020) ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis 14(1):4\u201322","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2238_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/ecco-jcc\/jjz187","volume":"14","author":"M Adamina","year":"2019","unstructured":"Adamina M et al (2019) ECCO guidelines on therapeutics in Crohn\u2019s disease: surgical treatment. J Crohns Colitis 14(2):155\u2013168","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2238_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1365-2036.2008.03753.x","volume":"28","author":"R Panaccione","year":"2008","unstructured":"Panaccione R et al (2008) Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 28(6):674\u2013688","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2238_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology 132(1):52\u201365","journal-title":"Gastroenterology"},{"issue":"9317","key":"2238_CR8","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB et al (2002) Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 359(9317):1541\u20131549","journal-title":"Lancet"},{"issue":"2","key":"2238_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology 130(2):323\u2013333","journal-title":"Gastroenterology"},{"issue":"6","key":"2238_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/1756283X11413315","volume":"4","author":"S Schreiber","year":"2011","unstructured":"Schreiber S (2011) Certolizumab pegol for the treatment of Crohn\u2019s disease. Therap Adv Gastroenterol 4(6):375\u2013389","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"2238_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa062897","volume":"357","author":"S Schreiber","year":"2007","unstructured":"Schreiber S et al (2007) Maintenance therapy with certolizumab pegol for Crohn\u2019s disease. N Engl J Med 357(3):239\u2013250","journal-title":"N Engl J Med"},{"issue":"11","key":"2238_CR12","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/ajg.2012.298","volume":"107","author":"L Peyrin-Biroulet","year":"2012","unstructured":"Peyrin-Biroulet L et al (2012) Surgery in a population-based cohort of Crohn\u2019s disease from Olmsted County, Minnesota (1970\u20132004). Am J Gastroenterol 107(11):1693\u20131701","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2238_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00535-003-1317-2","volume":"39","author":"A Yamaguchi","year":"2004","unstructured":"Yamaguchi A et al (2004) The clinical characteristics and outcome of intraabdominal abscess in Crohn\u2019s disease. J Gastroenterol 39(5):441\u2013448","journal-title":"J Gastroenterol"},{"issue":"4","key":"2238_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR et al (2018) ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol 113(4):481\u2013517","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2238_CR15","first-page":"175","volume":"5","author":"N Werbin","year":"2003","unstructured":"Werbin N et al (2003) Free perforation in Crohn\u2019s disease. Isr Med Assoc J 5(3):175\u2013177","journal-title":"Isr Med Assoc J"},{"issue":"2","key":"2238_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/SLA.0000000000002017","volume":"267","author":"A Brouquet","year":"2018","unstructured":"Brouquet A et al (2018) Anti-tnf therapy is associated with an increased risk of postoperative morbidity after surgery for ileocolonic Crohn disease: results of a prospective nationwide cohort. Ann Surg 267(2):221\u2013228","journal-title":"Ann Surg"},{"issue":"12","key":"2238_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/bjs.10595","volume":"104","author":"AB van Overstraeten","year":"2017","unstructured":"van Overstraeten AB et al (2017) Short- and medium-term outcomes following primary ileocaecal resection for Crohn\u2019s disease in two specialist centres. Br J Surg 104(12):1713\u20131722","journal-title":"Br J Surg"},{"issue":"10","key":"2238_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4240\/wjgs.v7.i10.237","volume":"7","author":"KT Crowell","year":"2015","unstructured":"Crowell KT, Messaris E (2015) Risk factors and implications of anastomotic complications after surgery for Crohn\u2019s disease. World J Gastrointest Surg 7(10):237\u2013242","journal-title":"World J Gastrointest Surg"},{"key":"2238_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/codi.13929","author":"PG Kotze","year":"2017","unstructured":"Kotze PG et al (2017) Adalimumab and postoperative complications of elective intestinal resections in Crohn\u2019s disease: a propensity score case-matched study. Colorectal Dis. https:\/\/doi.org\/10.1111\/codi.13929","journal-title":"Colorectal Dis"},{"issue":"4","key":"2238_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/DCR.0b013e3182759029","volume":"56","author":"MK Krane","year":"2013","unstructured":"Krane MK et al (2013) Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease. Dis Colon Rectum 56(4):449\u2013457","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"2238_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/BF02236563","volume":"43","author":"T Yamamoto","year":"2000","unstructured":"Yamamoto T, Allan RN, Keighley MR (2000) Risk factors for intra-abdominal sepsis after surgery in Crohn\u2019s disease. Dis Colon Rectum 43(8):1141\u20131145","journal-title":"Dis Colon Rectum"},{"issue":"10","key":"2238_CR22","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1007\/s11605-008-0646-0","volume":"12","author":"KA Appau","year":"2008","unstructured":"Appau KA et al (2008) Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn\u2019s patients. J Gastrointest Surg 12(10):1738\u20131744","journal-title":"J Gastrointest Surg"},{"issue":"8","key":"2238_CR23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/bjs.9152","volume":"100","author":"T Serradori","year":"2013","unstructured":"Serradori T et al (2013) The effect of immune therapy on surgical site infection following Crohn\u2019s disease resection. Br J Surg 100(8):1089\u20131093","journal-title":"Br J Surg"},{"issue":"5","key":"2238_CR24","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00268-009-9957-x","volume":"33","author":"AA Indar","year":"2009","unstructured":"Indar AA et al (2009) Effect of perioperative immunosuppressive medication on early outcome in Crohn\u2019s disease patients. World J Surg 33(5):1049\u20131052","journal-title":"World J Surg"},{"issue":"6","key":"2238_CR25","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/MEG.0000000000001944","volume":"33","author":"Z Moosvi","year":"2021","unstructured":"Moosvi Z et al (2021) Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 33(6):799\u2013816","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"2238_CR26","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/ibd.22954","volume":"18","author":"U Kopylov","year":"2012","unstructured":"Kopylov U et al (2012) Anti-tumor necrosis factor and postoperative complications in Crohn\u2019s disease: systematic review and meta-analysis. Inflamm Bowel Dis 18(12):2404\u20132413","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2238_CR27","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s10620-016-4400-2","volume":"62","author":"PG Kotze","year":"2017","unstructured":"Kotze PG et al (2017) Tumor necrosis factor alpha inhibitors did not influence postoperative morbidity after elective surgical resections in Crohn\u2019s disease. Dig Dis Sci 62(2):456\u2013464","journal-title":"Dig Dis Sci"},{"issue":"7","key":"2238_CR28","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/ecco-jcc\/jjaa268","volume":"15","author":"RS Shah","year":"2021","unstructured":"Shah RS et al (2021) Hypoalbuminaemia, not biologic exposure, is associated with postoperative complications in Crohn\u2019s disease patients undergoing ileocolic resection. J Crohns Colitis 15(7):1142\u20131151","journal-title":"J Crohns Colitis"},{"issue":"7","key":"2238_CR29","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/ecco-jcc\/jjac012","volume":"16","author":"MA Abd El Aziz","year":"2022","unstructured":"Abd El Aziz MA et al (2022) Postoperative safety profile of minimally invasive ileocolonic resections for Crohn\u2019s disease in the era of biologic therapy. J Crohns Colitis 16(7):1079\u20131088","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2238_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/ajg.2016.541","volume":"112","author":"M Fumery","year":"2017","unstructured":"Fumery M et al (2017) Postoperative complications after ileocecal resection in Crohn\u2019s disease: a prospective study from the REMIND group. Off J Am Coll Gastroenterol | ACG 112(2):337\u2013345","journal-title":"Off J Am Coll Gastroenterol | ACG"},{"issue":"1","key":"2238_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1053\/j.gastro.2022.03.057","volume":"163","author":"BL Cohen","year":"2022","unstructured":"Cohen BL et al (2022) Prospective Cohort study to investigate the safety of preoperative tumor necrosis factor inhibitor exposure in patients with inflammatory bowel disease undergoing intra-abdominal surgery. Gastroenterology 163(1):204\u2013221","journal-title":"Gastroenterology"},{"issue":"4","key":"2238_CR32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/ibd\/izx076","volume":"24","author":"AL Lightner","year":"2018","unstructured":"Lightner AL et al (2018) Postoperative outcomes in vedolizumab-treated patients undergoing major abdominal operations for inflammatory bowel disease: retrospective multicenter cohort study. Inflamm Bowel Dis 24(4):871\u2013876","journal-title":"Inflamm Bowel Dis"},{"key":"2238_CR33","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s00384-021-04017-2","volume":"36","author":"D Guo","year":"2021","unstructured":"Guo D et al (2021) Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis. Int J Colorectal Dis 36:2081\u20132092","journal-title":"Int J Colorectal Dis"},{"key":"2238_CR34","doi-asserted-by":"publisher","first-page":"175628481878361","DOI":"10.1177\/1756284818783614","volume":"11","author":"PG Kotze","year":"2018","unstructured":"Kotze PG et al (2018) Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. Therap Adv Gastroenterol 11:1756284818783614","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"2238_CR35","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00384-022-04140-8","volume":"37","author":"M Uchino","year":"2022","unstructured":"Uchino M et al (2022) Association between preoperative biologic use and surgical morbidity in patients with Crohn\u2019s disease. Int J Colorectal Dis 37(5):999\u20131010","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"2238_CR36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/ecco-jcc\/jjx163","volume":"12","author":"AL Lightner","year":"2017","unstructured":"Lightner AL et al (2017) Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn\u2019s disease. J Crohns Colitis 12(4):402\u2013407","journal-title":"J Crohns Colitis"},{"issue":"5","key":"2238_CR37","first-page":"691","volume":"34","author":"R Garg","year":"2021","unstructured":"Garg R et al (2021) Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn\u2019s disease: a systematic review and meta-analysis. Ann Gastroenterol 34(5):691\u2013698","journal-title":"Ann Gastroenterol"},{"issue":"3","key":"2238_CR38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4103\/wjcs.wjcs_29_22","volume":"11","author":"N Gupta","year":"2022","unstructured":"Gupta N et al (2022) Post-operative outcomes in patients undergoing abdominal surgery for Crohn\u2019s disease treated with pre-operative ustekinumab: a systematic review and meta-analysis. World J Colorectal Surg 11(3):60\u201367","journal-title":"World J Colorectal Surg"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-025-02238-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-025-02238-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-025-02238-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T17:23:19Z","timestamp":1757438599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-025-02238-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2238"],"URL":"https:\/\/doi.org\/10.1007\/s13304-025-02238-6","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"type":"print","value":"2038-131X"},{"type":"electronic","value":"2038-3312"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest regarding the publication of this paper. There are no financial interests, personal relationships, or direct academic competitions that could have influenced the work reported in this manuscript. No commercial or other sources of funding have been received by the individual authors or their associated departments or organizations that could raise questions of bias.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study complied with the ethical standards. The NSQIP database is a de-identified one, thus, our research is not a human subjects one and didn't require Institutional Review Board (IRB) review or obtaining informed consents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Standards, Research involving human participants and\/or animals, and Informed consent"}}]}}